Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data
Targeted Oncology · 2024-03 · 19 (2) · 213-221
DOI: 10.1007/s11523-024-01044-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Targeted Oncology, online erschienen am 28.02.2024. Verfasst von Alexander Olkus und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Infectious Diseases and Intoxication, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Ger…. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Bile Duct Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Krebshilfe, German Ministry of Research and Education, Universitätsklinikum Heidelberg.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Infectious Diseases and Intoxication, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
- Liver Cancer Center Heidelberg, Heidelberg, Germany.
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany.
- National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.
- Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
ORCID-Profile: Michael T Dill
Förderung
- Deutsche Krebshilfe
- German Ministry of Research and Education
- Universitätsklinikum Heidelberg
Zitieren
APA
Olkus, A., Tomczak, A., Berger, A. K., Rauber, C., Puchas, P., Wehling, C., Longerich, T., Mehrabi, A., Chang, D. H., Liermann, J., Schäfer, S., Pfeiffenberger, J., Jäger, D., Michl, P., Springfeld, C., & Dill, M. T. (2024). Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data. Targeted Oncology, 19(2), 213-221. https://doi.org/10.1007/s11523-024-01044-1
Vancouver
Olkus A, Tomczak A, Berger AK, Rauber C, Puchas P, Wehling C, et al. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data. Targeted Oncology. 2024;19(2):213-221. doi:10.1007/s11523-024-01044-1
BibTeX
@article{Olkus2024,
author = {Olkus, Alexander and Tomczak, Aurelie and Berger, Anne Katrin and Rauber, Conrad and Puchas, Philip and Wehling, Cyrill and Longerich, Thomas and Mehrabi, Arianeb and Chang, De-Hua and Liermann, Jakob and Schäfer, Sophia and Pfeiffenberger, Jan and Jäger, Dirk and Michl, Patrick and Springfeld, Christoph and Dill, Michael T},
title = {Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data},
journal = {Targeted Oncology},
year = {2024},
volume = {19},
number = {2},
pages = {213--221},
doi = {10.1007/s11523-024-01044-1}
}
EUVIMED